WO2001083527A3 - Glucagon antagonists - Google Patents
Glucagon antagonists Download PDFInfo
- Publication number
- WO2001083527A3 WO2001083527A3 PCT/US2001/014321 US0114321W WO0183527A3 WO 2001083527 A3 WO2001083527 A3 WO 2001083527A3 US 0114321 W US0114321 W US 0114321W WO 0183527 A3 WO0183527 A3 WO 0183527A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- domain
- vehicle
- glucagon antagonist
- preferred
- glucagon
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title abstract 6
- 108060003199 Glucagon Proteins 0.000 title abstract 6
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 6
- 229960004666 glucagon Drugs 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 5
- 229920002307 Dextran Polymers 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002823 phage display Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001580951A JP2003531632A (en) | 2000-05-03 | 2001-05-03 | Glucagon antagonist |
AU2001255798A AU2001255798A1 (en) | 2000-05-03 | 2001-05-03 | Glucagon antagonists |
EP01929003A EP1278772A2 (en) | 2000-05-03 | 2001-05-03 | Glucagon antagonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20143600P | 2000-05-03 | 2000-05-03 | |
US60/201,436 | 2000-05-03 | ||
US09/847,249 | 2001-05-02 | ||
US09/847,249 US6677136B2 (en) | 2000-05-03 | 2001-05-02 | Glucagon antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001083527A2 WO2001083527A2 (en) | 2001-11-08 |
WO2001083527A3 true WO2001083527A3 (en) | 2002-08-01 |
Family
ID=26896746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/014321 WO2001083527A2 (en) | 2000-05-03 | 2001-05-03 | Glucagon antagonists |
Country Status (5)
Country | Link |
---|---|
US (1) | US6677136B2 (en) |
EP (1) | EP1278772A2 (en) |
JP (1) | JP2003531632A (en) |
AU (1) | AU2001255798A1 (en) |
WO (1) | WO2001083527A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7562012B1 (en) * | 2000-11-03 | 2009-07-14 | Audible Magic Corporation | Method and apparatus for creating a unique audio signature |
CN1774232B (en) * | 2002-11-25 | 2012-05-09 | 金克克国际有限公司 | Skin or hair binding peptides |
WO2004111078A2 (en) * | 2003-06-18 | 2004-12-23 | Theratechnologies Inc. | Compounds that modulate the glucagon response and uses thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
KR20050047030A (en) | 2003-11-13 | 2005-05-19 | 한미약품 주식회사 | Igg fc fragment for a drug carrier and method for the preparation thereof |
US20050222040A1 (en) * | 2004-04-05 | 2005-10-06 | Blm Group, Inc. | Vertebrate peptide modulators of lipid metabolism |
US20190330295A1 (en) * | 2005-05-04 | 2019-10-31 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
CN101534846B (en) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | Glucagon analogs exhibiting physiological solubility and stability |
WO2007100535A2 (en) * | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
US8669228B2 (en) * | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
AU2008216265B2 (en) * | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
CA2707861A1 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
JP5771005B2 (en) * | 2007-10-30 | 2015-08-26 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Glucagon antagonist and compound showing GLP-1 agonist activity |
AU2009210570B2 (en) * | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
CN102088989B (en) * | 2008-06-17 | 2014-11-26 | 印第安纳大学研究及科技有限公司 | Glucagon analogs exhibiting enhanced solubility and stability physiological pH buffers |
PE20100255A1 (en) | 2008-06-17 | 2010-04-25 | Univ Indiana Res & Tech Corp | GLUCAGON / GLP-1 RECEPTOR CO-AGONISTS |
TWI474835B (en) * | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
JP2012512903A (en) | 2008-12-19 | 2012-06-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | Amide glucagon superfamily peptide prodrug |
AU2010260058B2 (en) | 2009-06-16 | 2015-09-24 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
CA2788304A1 (en) | 2010-01-27 | 2011-08-04 | Indiana University Research And Technology Corporation | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
KR20130062931A (en) | 2010-05-13 | 2013-06-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
RU2580317C2 (en) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Peptide pro-drugs of amide glucagon superfamily |
EA201390941A1 (en) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | GLUCAGON ANALOGUES, EXPERIENCING ACTIVITY ON GIP RECEPTOR |
EP3434687B1 (en) | 2011-06-10 | 2021-03-10 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
RU2733544C2 (en) * | 2011-06-17 | 2020-10-05 | Ханми Сайенс Ко., Лтд. | Conjugate containing oxintomodulin and immunoglobulin fragment, and its application |
US9309301B2 (en) | 2011-06-22 | 2016-04-12 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
JP6396211B2 (en) * | 2011-07-04 | 2018-09-26 | インペリアル・イノベイションズ・リミテッド | New compounds and their effects on feeding behavior |
CN103958682A (en) * | 2011-10-21 | 2014-07-30 | 诺松制药股份公司 | Glucagon binding nucleic acids |
CA2847246A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
ES2602486T3 (en) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Glucagon analogs showing GIP receptor activity |
KR101968344B1 (en) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | A composition for treating hyperlipidemia comprising oxyntomodulin analog |
ES2748158T3 (en) | 2012-11-06 | 2020-03-13 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (en) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
US20160024169A1 (en) | 2013-03-14 | 2016-01-28 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
TWI802396B (en) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
CN108271356A (en) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | Duodenin-insulin conjugate |
KR102418477B1 (en) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | Gluagon Derivatives |
US11135271B2 (en) | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
MA49545B1 (en) | 2015-06-30 | 2022-03-31 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and composition comprising a long-acting conjugate thereof |
CN116063454A (en) | 2015-12-31 | 2023-05-05 | 韩美药品株式会社 | glucagon/GLP-1/GIP receptor triple agonists |
UA126662C2 (en) | 2016-06-29 | 2023-01-11 | Ханмі Фарм. Ко., Лтд. | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereofgj[slyt uk. |
EP3842449A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
EP3842061A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
US20230365623A1 (en) * | 2020-09-04 | 2023-11-16 | Florey Institute of Neuroscience and Mental Health | Derivatisation of peptides and proteins |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017039A1 (en) * | 1993-01-19 | 1994-08-04 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5408037A (en) * | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
WO1997034631A1 (en) * | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998028427A1 (en) * | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
DE69312700T2 (en) | 1992-04-14 | 1998-02-19 | Cornell Res Foundation Inc | MACROMOLECULES BASED ON DENDRITIC POLYMERS AND METHOD FOR THE PRODUCTION THEREOF |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
JP2001512560A (en) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | Methods and means for the selection of peptides and proteins with specific affinity for a target |
CA2382165A1 (en) * | 1999-12-08 | 2001-06-14 | Genset S.A. | Full-length human cdnas encoding potentially secreted proteins |
-
2001
- 2001-05-02 US US09/847,249 patent/US6677136B2/en not_active Expired - Fee Related
- 2001-05-03 EP EP01929003A patent/EP1278772A2/en not_active Withdrawn
- 2001-05-03 WO PCT/US2001/014321 patent/WO2001083527A2/en active Search and Examination
- 2001-05-03 AU AU2001255798A patent/AU2001255798A1/en not_active Abandoned
- 2001-05-03 JP JP2001580951A patent/JP2003531632A/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5408037A (en) * | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
WO1994017039A1 (en) * | 1993-01-19 | 1994-08-04 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US5665705A (en) * | 1993-12-29 | 1997-09-09 | The Rockefeller University | Glucagon analogs with serine replacements |
WO1997034631A1 (en) * | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO1998028427A1 (en) * | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
Also Published As
Publication number | Publication date |
---|---|
US20030032588A1 (en) | 2003-02-13 |
JP2003531632A (en) | 2003-10-28 |
AU2001255798A1 (en) | 2001-11-12 |
WO2001083527A2 (en) | 2001-11-08 |
EP1278772A2 (en) | 2003-01-29 |
US6677136B2 (en) | 2004-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001083527A3 (en) | Glucagon antagonists | |
WO2001081376A3 (en) | Apo-ai/aii peptide derivatives | |
WO2004043382A3 (en) | Enhanced variants of erythropoietin and methods of use | |
EP2261247A3 (en) | KDR peptides and vaccines comprising the same | |
WO2005115306A3 (en) | Keratin-binding polypeptides | |
JP2004534503A5 (en) | ||
WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
BR9914066A (en) | Human complement c3-degrading polypeptide from streptococcus pneumoniae | |
WO2003048205A3 (en) | Novel proteins with il-6 inhibiting activity | |
WO2001083526A3 (en) | Calcitonin-related molecules | |
WO2005072766A3 (en) | Peptides that bind to hsp90 proteins | |
EP1500700A3 (en) | Pectic acid lyase | |
WO2006029343A3 (en) | Peptides that selectively home to heart vasculature and related conjugates and methods | |
WO2002102847A1 (en) | Novel ligand and dna thereof | |
WO2005041882A3 (en) | Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs | |
WO2001092468A3 (en) | Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof | |
WO2007073845A8 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof | |
CA2530731A1 (en) | Peptide having apoptosis-inhibiting activity | |
WO2002083727A3 (en) | Nucleic acid sequences of hyperplasies and tumors of the thyroid | |
WO2002059317A3 (en) | Cub domain protein zcub3 and materials and methods for making it | |
Marchetto et al. | Two short peptides including segments of subunit A of Escherichia coli DNA gyrase as potential probes to evaluate the antibacterial activity of quinolones | |
WO2009069546A1 (en) | Therapeutic or prophylactic agent, detection method and detection agent for metabolic syndrome, and method for screening of candidate compound for therapeutic agent for metabolic syndrome | |
Geraghty | Structure-function studies of analogues of FMRFamide in Helix aspersa. | |
EP1583587A2 (en) | Organic compounds with biological action as thrombin inhibitors and use therof | |
WO2002029053A1 (en) | Novel g protein-coupled receptor protein and dna thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001929003 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001929003 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001929003 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |